deltatrials
Completed PHASE3 NCT00035295

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)

A Double-Blind, Multicenter, Placebo-and Active-Controlled Acute and Extension Study of 2 Doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder

Sponsor: Merck Sharp & Dohme LLC

Conditions Major Depressive Disorder
Interventions Comparator: placebo MK0869, aprepitant
Updated 8 times since 2017 Last updated: Apr 17, 2017 Started: Nov 8, 2001 Primary completion: Dec 5, 2003 Completion: Dec 5, 2003

This PHASE3 trial investigates Major Depressive Disorder and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 8 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jun 2022 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. May 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Feb 2017 — May 2017 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Nov 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.